Gene therapies are a promising new class of medicines known as advanced-therapy medicinal products. While there is a lot of excitement in the scientific and medical community around the promise of these therapies, the reality is that bringing any new innovation to market is challenging.
Ferring Pharmaceutical’s David Bell, Vice President of the Uro-Oncology Business Unit, can talk about how biopharma companies can overcome these challenges to successfully bring innovative products such as gene therapies to market at scale. This presentation will discuss:
- The importance of launching a product right the first time.
- The evolution of prelaunch activities and launch planning.
- Establishing strong and diversified manufacturing capabilities to meet the growing needs of patients beyond launch.
- Value strategies that drive the efforts needed to ensure coverage and reimbursement.
- How to reduce the financial burden on patients through access programs and partnerships – especially for oncology patients.
- Working with and educating healthcare providers to help disrupt standards of care for the betterment of patients.
- Commercialization strategies and considerations for engaging providers and patients around breakthrough, novel therapeutics.
Speakers 
Vice President, Uro-Oncology, Ferring Pharmaceuticals
Tuesday October 1, 2024 2:00pm - 2:30pm EDT
Log in to leave feedback.
Feedback Submitted
